Exchange: NASDAQ·Updated 01:40 PM EDT
News
all
press releases
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows...
Yahoo! Finance: News
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +21.81% and -4.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Qiagen (QGEN) Q1 Earnings and Revenues Lag Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of -1.23% and -0.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Caribou Biosciences (NASDAQ:CRBU) Stock Price Down 2.3% - Here's Why
Caribou Biosciences (NASDAQ:CRBU) Stock Price Down 2.3% - What's Next...
MarketBeat
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Zacks
Three Best Genomics Stocks for Your Portfolio in 2026
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Zacks
Caribou Biosciences' (CRBU) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Tuesday...
MarketBeat

Advertisement|Remove ads.